{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:34:13Z","timestamp":1771263253920,"version":"3.50.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SANDER18Y7"],"award-info":[{"award-number":["SANDER18Y7"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SINGH19R0"],"award-info":[{"award-number":["SINGH19R0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000098","name":"National Institutes of Health Clinical Center","doi-asserted-by":"publisher","award":["K24HL141669"],"award-info":[{"award-number":["K24HL141669"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SANDER18Y7"],"award-info":[{"award-number":["SANDER18Y7"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SINGH19R0"],"award-info":[{"award-number":["SINGH19R0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"National Institutes of Health Clinical Center","doi-asserted-by":"publisher","award":["K24HL141669"],"award-info":[{"award-number":["K24HL141669"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale\/Objectives<\/jats:title>\n                    <jats:p>Antibiotic selection for in-hospital treatment of pulmonary exacerbations (PEx) in people with cystic fibrosis (CF) is typically guided by previous respiratory culture results or past PEx antibiotic treatment. In the absence of clinical improvement during PEx treatment, antibiotics are frequently changed in search of a regimen that better alleviates symptoms and restores lung function. The clinical benefits of changing antibiotics during PEx treatment are largely uncharacterized<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study using the Cystic Fibrosis Foundation Patient Registry Pediatric Health Information System. PEx were included if they occurred in children with CF from 6 to 21\u2009years old who had been treated with intravenous antibiotics between January 1, 2006, and December 31, 2018. PEx with lengths of stay &amp;lt;5 or &amp;gt;21\u2009days or for which treatment was delivered in an intensive care unit were excluded. An antibiotic change was defined as the addition or subtraction of any intravenous antibiotic between Hospital Day 6 and the day before hospital discharge. Inverse probability of treatment weighting was used to adjust for disease severity and indication bias, which might influence a decision to change antibiotics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In all, 4,099 children with CF contributed 18,745 PEx for analysis, of which 8,169 PEx (43.6%) included a change in intravenous antibiotics on or after Hospital Day 6. The mean change in pre- to post-treatment percent predicted forced expiratory volume in 1\u2009second (ppFEV1) was 11.3 (standard error, 0.21) among events in which an intravenous antibiotic change occurred versus 12.2 (0.18) among PEx without an intravenous antibiotic change (P\u2009=\u20090.001). Similarly, the odds of return to \u2a7e90% of baseline ppFEV1 were less for PEx with antibiotic changes than for those without changes (odds ratio [OR], 0.89 [95% confidence interval (CI), 0.80\u20130.98]). The odds of returning to \u2a7e100% of baseline ppFEV1 did not differ between PEx with versus without antibiotic changes (OR, 0.94 [95% CI, 0.86\u20131.03]). In addition, PEx treated with intravenous antibiotic changes were associated with higher odds of future PEx (OR, 1.17 [95% CI, 1.12\u20131.22]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this retrospective study, changing intravenous antibiotics during PEx treatment in children with CF was common and not associated with improved clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202301-078oc","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T16:44:26Z","timestamp":1686933866000},"page":"1293-1298","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":4,"title":["Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment"],"prefix":"10.1093","volume":"20","author":[{"given":"Jonathan D.","family":"Cogen","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Seattle Children\u2019s Hospital, University of Washington, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don B.","family":"Sanders","sequence":"additional","affiliation":[{"name":"Division of Pediatric Pulmonology, Allergy and Sleep Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Slaven","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna V.","family":"Faino","sequence":"additional","affiliation":[{"name":"Core for Biostatistics, Epidemiology and Analytics in Research, Seattle Children\u2019s Research Institute, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjani","family":"Somayaji","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron L.","family":"Gibson","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Seattle Children\u2019s Hospital, University of Washington, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas R.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Seattle Children\u2019s Hospital, University of Washington, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement L.","family":"Ren","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Children\u2019s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"2026012203283621600_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jpeds.2005.10.019","article-title":"Cystic fibrosis pulmonary exacerbations","volume":"148","author":"Ferkol","year":"2006","journal-title":"J Pediatr"},{"key":"2026012203283621600_bib2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/thx.2006.060889","article-title":"Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis","volume":"62","author":"Goss","year":"2007","journal-title":"Thorax"},{"key":"2026012203283621600_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1183\/09031936.00159111","article-title":"Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis","volume":"40","author":"Waters","year":"2012","journal-title":"Eur Respir J"},{"key":"2026012203283621600_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1378\/chest.121.1.64","article-title":"Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis","volume":"121","author":"Britto","year":"2002","journal-title":"Chest"},{"key":"2026012203283621600_bib5","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203283621600_bib6","doi-asserted-by":"crossref","first-page":"e20162642","DOI":"10.1542\/peds.2016-2642","article-title":"Characterization of inpatient cystic fibrosis pulmonary exacerbations","volume":"139","author":"Cogen","year":"2017","journal-title":"Pediatrics"},{"key":"2026012203283621600_bib7","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ppul.22652","article-title":"Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis","volume":"48","author":"Wagener","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"2026012203283621600_bib8","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcf.2017.04.005","article-title":"Standardized Treatment of Pulmonary Exacerbations (STOP) study: observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations","volume":"16","author":"Sanders","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2026012203283621600_bib9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jcf.2022.05.010","article-title":"The effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations","volume":"21","author":"Zikic","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026012203283621600_bib10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jcf.2019.05.012","article-title":"The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations","volume":"18","author":"Cogen","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2026012203283621600_bib11","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203283621600_bib12","author":"Children\u2019s Hospital Association"},{"key":"2026012203283621600_bib13","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ppul.24272","article-title":"Linkage of the CF Foundation Patient Registry with the pediatric health information system database","volume":"54","author":"Cogen","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"2026012203283621600_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ppul.24527","article-title":"Evaluation of hospitalization data for the CFFPR-PHIS linked data set","volume":"55","author":"Cogen","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2026012203283621600_bib15","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/ppul.24577","article-title":"Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis","volume":"55","author":"Wagener","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2026012203283621600_bib16","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/cid\/ciab525","article-title":"Association between number of intravenous antipseudomonal antibiotics and clinical outcomes of pediatric cystic fibrosis pulmonary exacerbations","volume":"73","author":"Cogen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026012203283621600_bib17","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1513\/AnnalsATS.202111-1294OC","article-title":"Clinical outcomes of antipseudomonal versus other antibiotics among children with cystic fibrosis without Pseudomonas aeruginosa","volume":"19","author":"Cogen","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203283621600_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jcf.2020.05.008","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis","volume":"20","author":"VanDevanter","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026012203283621600_bib19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jpids\/pix064","article-title":"Accuracy of administrative data for antimicrobial administration in hospitalized children","volume":"7","author":"Courter","year":"2018","journal-title":"J Pediatric Infect Dis Soc"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/20\/9\/1293\/66268917\/annalsats_20_9_1293.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/20\/9\/1293\/66268917\/annalsats_20_9_1293.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:29:52Z","timestamp":1769070592000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/20\/9\/1293\/8414535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,1]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202301-078oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,9,1]]},"assertion":[{"value":"2023-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}